90 related articles for article (PubMed ID: 16531248)
1. Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation.
van der Velden VH
Haematologica; 2006 Mar; 91(3):291A. PubMed ID: 16531248
[No Abstract] [Full Text] [Related]
2. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.
Golay J; Cortiana C; Manganini M; Cazzaniga G; Salvi A; Spinelli O; Bassan R; Barbui T; Biondi A; Rambaldi A; Introna M
Haematologica; 2006 Mar; 91(3):322-30. PubMed ID: 16531255
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a new human pre-B acute lymphoblastic leukemia cell line (KMO-90) with 1;19 translocation carrying p53 gene alterations.
Sotomatsu M; Hayashi Y; Kawamura M; Yugami S; Shitara T
Leukemia; 1993 Oct; 7(10):1615-20. PubMed ID: 8412323
[TBL] [Abstract][Full Text] [Related]
4. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
[TBL] [Abstract][Full Text] [Related]
5. Campath-1H.
Sorokin P
Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
[TBL] [Abstract][Full Text] [Related]
6. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
7. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
8. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
10. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
[TBL] [Abstract][Full Text] [Related]
11. Severe migratory polyarthritis following in vivo CAMPATH-1G.
Varadi G; Or R; Rund D; Orbach H; Slavin S; Nagler A
Bone Marrow Transplant; 1995 Dec; 16(6):843-5. PubMed ID: 8750280
[TBL] [Abstract][Full Text] [Related]
12. Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3.
Ohyashiki K; Fujieda H; Miyauchi J; Ohyashiki JH; Tauchi T; Saito M; Nakazawa S; Abe K; Yamamoto K; Clark SC
Leukemia; 1991 Apr; 5(4):322-31. PubMed ID: 2027299
[TBL] [Abstract][Full Text] [Related]
13. Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
Osborne WL; Lennard AL
Haematologica; 2005 Jan; 90(1):ECR05. PubMed ID: 15653459
[TBL] [Abstract][Full Text] [Related]
14. Severe diarrhoea during Campath-1H treatment for refractory cutaneous T-cell lymphoma.
Goteri G; Rupoli S; Tassetti A; Pulini S; Morichetti D; Filosa A; Mandolesi A; Veccia S; Leoni P; Bearzi I
Ann Hematol; 2006 Sep; 85(9):617-9. PubMed ID: 16821018
[No Abstract] [Full Text] [Related]
15. Monoclonal antibodies and complement purged autograft in Burkitt lymphoma and lymphoblastic leukemia.
Favrot M; Philip I; Combaret V; Pavone E; Bouffet E; Biron P; Philip T
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():202-4. PubMed ID: 2713555
[No Abstract] [Full Text] [Related]
16. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy.
Hill P; Gagliardini E; Ruggenenti P; Remuzzi G
Nephrol Dial Transplant; 2005 Aug; 20(8):1741-4. PubMed ID: 15870227
[No Abstract] [Full Text] [Related]
17. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
[TBL] [Abstract][Full Text] [Related]
18. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
[TBL] [Abstract][Full Text] [Related]
19. Analysis of balanced rearrangements of chromosome 6 in acute leukemia: clustered breakpoints in q22-q23 and possible involvement of c-MYB in a new recurrent translocation, t(6;7)(q23;q32 through 36).
Sinclair P; Harrison CJ; Jarosová M; Foroni L
Haematologica; 2005 May; 90(5):602-11. PubMed ID: 15921375
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
